Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Autolus Therapeutics plc filings document a foreign-issuer ADS structure and material events for a commercial-stage T cell therapy company. The company’s American Depositary Shares trade on the Nasdaq Global Select Market, with each ADS representing one ordinary share, while the ordinary shares are registered in connection with the ADS listing.
Recent Form 8-K disclosures cover financial results, corporate presentations, AUCATZYL revenue updates, pipeline and manufacturing matters, and a master service agreement for lentiviral vector supply used in CAR-T products. The filings also record operational efficiency costs, changes in the company’s independent registered public accounting firm, internal-control disclosures, executive and compensation matters, governance actions and Regulation FD materials.
Autolus Therapeutics plc ownership update: MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman report beneficial ownership of 33,621,487 ADS (each ADS represents one ordinary share), equal to 12.6% of the outstanding ordinary shares. The percent calculation is based on 266,155,786 ordinary shares outstanding as of May 13, 2026, as reported in the issuer's Form 10-Q. The filing shows shared voting and dispositive power over the 33,621,487 ADS and is signed by Michael A. Kaufman.
Autolus Therapeutics plc received a Schedule 13G/A amendment disclosing that Armistice Capital, LLC and Steven Boyd collectively report beneficial ownership of 15,800,000 American Depositary Shares, representing 5.94% of the ADS class. The filing states Armistice Capital exercises shared voting and dispositive power over those shares under an Investment Management Agreement and is filed as a joint statement dated May 15, 2026.
Autolus Therapeutics plc reports Q1 2026 product revenue of $26.2 million, up from $9.0 million in Q1 2025, driven by AUCATZYL sales in the U.S. and the January 2026 U.K. launch. Despite this growth, the company recorded a net loss of $71.6 million and an operating loss of $59.5 million, with total comprehensive loss of $72.9 million.
Cash, cash equivalents and marketable securities totaled $229.4 million as of March 31, 2026, and management expects these resources to fund operations for at least one year from the statements’ issuance date. Autolus reports liabilities related to future royalties and milestones of $289.2 million, primarily tied to Blackstone and BioNTech funding arrangements.
The company continues to advance obe-cel across additional indications, including lupus nephritis, progressive multiple sclerosis and pediatric B-ALL, and is developing AUTO8 in AL amyloidosis. After quarter end, Autolus approved a restructuring plan, including a workforce reduction of about 13%, targeting annual operating expense savings of approximately $15 million from 2027.
Autolus Therapeutics reported strong commercial momentum for AUCATZYL in the first quarter of 2026, with net product revenue rising to $26.2 million from $9.0 million a year earlier. This shift supported the company’s first positive gross margin for its acute lymphoblastic leukemia business.
Despite this progress, Autolus remains loss-making, with a Q1 2026 net loss of $71.6 million and basic and diluted net loss per share of $(0.27). The company is executing a cost reduction plan, including a workforce reduction of about 13% and expects annualized operating expense savings of roughly $15 million from 2027, after about $8 million in restructuring charges. Management reaffirmed 2026 AUCATZYL net product revenue guidance of $120–$135 million and expects existing cash, cash equivalents and marketable securities of $229.4 million as of March 31, 2026 to fund operations into Q4 2027.
Autolus Therapeutics plc is implementing a restructuring plan that includes a reduction in force affecting approximately 13% of its workforce, leading to estimated total restructuring charges of about $8 million, primarily for severance and related costs. The company expects to record a significant portion of these charges in the first half of 2026 and to substantially complete the workforce reduction by the third quarter of 2026.
Autolus projects that these actions will reduce operating expenses by approximately $15 million on an annualized basis beginning in 2027. It confirmed financial guidance for full-year 2026 AUCATZYL net product revenue of $120 million to $135 million and, based on current plans, continues to expect its cash, cash equivalents and marketable securities to fund operations into the fourth quarter of 2027.
Autolus Therapeutics plc has changed its independent registered public accounting firm, dismissing Ernst & Young LLP (UK) and appointing Ernst & Young LLP (US) for the fiscal year ending December 31, 2026. The company states there were no disagreements with EY UK on accounting, disclosure, or audit matters and no reportable events, other than previously disclosed material weaknesses in internal control over financial reporting as of March 31, 2024. EY UK’s audit reports for the years ended December 31, 2025 and 2024 contained unmodified opinions, and EY UK has provided a letter to the SEC agreeing with the company’s description of the relationship.
Autolus Therapeutics plc filed a shelf registration on Form S-3 to offer, from time to time, up to $150,000,000 of ordinary shares, American Depositary Shares, debt securities and warrants. The prospectus is a general shelf: specific terms and any proceeds per offering will be set forth in prospectus supplements.
As context, the company reported 266,143,286 ordinary shares issued as of December 31, 2025. The prospectus states net proceeds will be used for clinical development, manufacturing, commercialization and general corporate purposes.
Autolus Therapeutics plc filed a registration statement on Form S-3 to register the resale by selling securityholders of up to 54,584,250 American Depositary Shares (ADSs). The amount comprises 51,318,944 ADSs previously issued and 3,265,306 ADSs issuable upon exercise of outstanding warrants. The company states the registration is being filed to satisfy contractual registration rights and that Autolus will receive no proceeds from sales by the selling securityholders. The ADSs trade on Nasdaq under the symbol AUTL; the prospectus cites a closing price of $1.47 per ADS on April 9, 2026. The filing describes customary resale methods, potential hedging and short-selling by purchasers or broker-dealers, indemnification arrangements and estimated registration expenses.